Aileron Therapeutics Reports Third Quarter 2019 Results
07 nov. 2019 07h30 HE
|
Aileron Therapeutics, Inc.
Announced positive interim results from its ongoing Phase 2a clinical trial evaluating the combination of ALRN-6924 and Pfizer’s IBRANCE® (palbociclib) for the treatment of patients with tumors...
Aileron Therapeutics to Report Third Quarter 2019 Financial Results on November 7th
31 oct. 2019 08h30 HE
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, today announced that the...
Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference
29 oct. 2019 08h00 HE
|
Aileron Therapeutics, Inc.
Nonclinical research results show that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells and enhanced the anti-cancer activity of chemotherapy ALRN-6924 could enable a...
Aileron to Present Nonclinical Myelopreservation Data for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference on October 29th
21 oct. 2019 08h00 HE
|
Aileron Therapeutics, Inc.
Nonclinical research showed that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells without inhibiting the anti-cancer activity of chemotherapy. ALRN-6924 could enable a...
Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent
16 oct. 2019 08h30 HE
|
Aileron Therapeutics, Inc.
Treatment uses a precision-medicine strategy to prevent the toxic side-effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer. ...
Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology
28 sept. 2019 07h30 HE
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., Sept. 28, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients,...
Aileron to Present Interim Phase 2a Clinical Data for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers at the 2019 Congress of the European Society for Medical Oncology
24 sept. 2019 17h00 HE
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients,...
Aileron Therapeutics Announces Management Change
09 sept. 2019 08h00 HE
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other...
Aileron Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference in New York
03 sept. 2019 17h10 HE
|
Aileron Therapeutics, Inc.
WATERTOWN, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other...
Aileron Therapeutics Reports Second Quarter 2019 Financial Results
06 août 2019 16h10 HE
|
Aileron Therapeutics, Inc.
Enrollment in Phase 2a expansion cohort testing ALRN-6924 in combination with Pfizer’s IBRANCE® (palbociclib) in MDM2-amplified cancers ongoing and ahead of schedule. Interim data on at least 15...